Last reviewed · How we verify
NCT04630327
Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory
trial testing Beck Depression Inventory-21 (diagnostic survey) in Depression in 226 participants. Completed in 1 May 2022.
28 April 2022
Quick facts
| Lead sponsor | Kazakh Medical University of Continuing Education |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 226 |
| Start date | 13 January 2020 |
| Primary completion | 28 April 2022 |
| Estimated completion | 1 May 2022 |
| Sites | 2 locations across Kazakhstan |
Drugs / interventions tested
- Beck Depression Inventory-21 (diagnostic survey)
- Beck Anxiety Inventory
- Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria
Conditions studied
- Depression — all drugs for Depression →
- Anxiety — all drugs for Anxiety →
- Breast Cancer — all drugs for Breast Cancer →
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Kazakh Medical University of Continuing Education
Who can join
Adults 18 to 65, female only, with Depression or Anxiety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Depression and anxiety in female patients with cancer are serious comorbidities that affect the quality of life for patients and their survival rates as they have poorer health outcomes. This validation study is a part of the study on the prevalence of depression and anxiety among breast cancer patients. This study aims to investigate the validity of the Kazakh and Russian versions of the Beck Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI) among female cancer patients in Almaty, Kazakhstan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04630327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Other Kazakh Medical University of Continuing Education trials
Trials by the same sponsor.
- NCT05011409 — Prevalence of Depression and Anxiety Among Breast Cancer Patients · completed
- NCT04771221 — Method of Early Diagnosis of Laryngopharyngeal Reflux · NA · completed
- NCT05296655 — Kazakh Version of Reflux Symptom Index · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04630327 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kazakh Medical University of Continuing Education
- Last refreshed: 21 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04630327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing